DEXEDRINE SPANSULE (dextroamphetamine sulfate) by R-Pharm US is clinical pharmacology amphetamines are noncatecholamine, sympathomimetic amines with cns stimulant activity. First approved in 1976.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
DEXEDRINE SPANSULE is an extended-release oral capsule containing dextroamphetamine sulfate, a CNS stimulant that elevates sympathomimetic activity. It is indicated for attention deficit disorders and narcolepsy, working through noncatecholamine mechanisms that enhance mental and behavioral focus. The sustained-release formulation delivers drug gradually over ~8 hours, achieving lower peak concentrations than immediate-release tablets while maintaining similar overall bioavailability.
With LOE approaching and zero linked job openings, this product is in managed decline; career roles will focus on legacy support and transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Amphetamines are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence that clearly…
Worked on DEXEDRINE SPANSULE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
DEXEDRINE SPANSULE offers limited career growth opportunity as a legacy product approaching loss of exclusivity with zero current job openings. Working on this brand involves defensive commercial strategy, generic transition planning, and compliance oversight rather than innovation-driven career advancement.